Curis (CRIS) & Aurigene Report CA-170 Program Update Following Data Presented at ESMO 2017
Tweet Send to a Friend
Curis, Inc. (NASDAQ: CRIS) today presented preliminary data from the initial 34 patients with cancer treated in the dose escalation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
